KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeMD (LFMD) EBITDA (2016 - 2025)

Historic EBITDA for LifeMD (LFMD) over the last 14 years, with Q3 2025 value amounting to -$2.0 million.

  • LifeMD's EBITDA rose 5072.37% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.3 million, marking a year-over-year increase of 7162.88%. This contributed to the annual value of -$18.3 million for FY2024, which is 2613.69% down from last year.
  • LifeMD's EBITDA amounted to -$2.0 million in Q3 2025, which was up 5072.37% from -$451562.0 recorded in Q2 2025.
  • In the past 5 years, LifeMD's EBITDA ranged from a high of $974342.0 in Q1 2025 and a low of -$16.1 million during Q2 2021
  • In the last 5 years, LifeMD's EBITDA had a median value of -$6.2 million in 2024 and averaged -$7.1 million.
  • As far as peak fluctuations go, LifeMD's EBITDA crashed by 58476.32% in 2021, and later skyrocketed by 11578.84% in 2025.
  • Quarter analysis of 5 years shows LifeMD's EBITDA stood at -$13.7 million in 2021, then rose by 24.1% to -$10.4 million in 2022, then skyrocketed by 79.06% to -$2.2 million in 2023, then tumbled by 76.98% to -$3.8 million in 2024, then soared by 48.76% to -$2.0 million in 2025.
  • Its EBITDA stands at -$2.0 million for Q3 2025, versus -$451562.0 for Q2 2025 and $974342.0 for Q1 2025.